Riding high on some promising Phase I data, Biogen has mapped out a big late-stage program for its Alzheimer's disease treatment, making a risky bet that it can reverse decades of failure in the field.
AstraZeneca signed a pair of agreements centered on its most prized cancer therapy, selling a stake to the hematology experts at Celgene and buying the rights to a complementary treatment from Innate Pharma.
Roche is not wasting any time after sealing its $1.2 billion deal for Foundation Medicine, charging full speed ahead with the companies' planned cancer R&D collaboration to generate growth in the coming year.
Juno Therapeutics and AstraZeneca are joining forces to test their respective cancer treatments in tandem, combining newfangled therapies that promise to use the immune system to combat tumors.
Months removed from buying its way into the world of Big Data genomics, Chinese CRO WuXi PharmaTech has partnered up with DNAnexus to take its technology to the cloud.
The need for cold-chain transportation has been a prominent barrier in making vaccines available to developing countries. A consortium led by Mymetics' Dutch subsidiary has just received €8.4 million to change that.
PPD has opened a new central lab facility in Shanghai, expanding its testing services into China as it stretches out around the globe.
While Merck and Bristol-Myers Squibb grab global headlines with treatments designed to make it harder for cancer to hide from the immune system, Cambridge, MA's Jounce Therapeutics is coming at it from the other end, crafting a therapy that revs up the body's natural defenses to attack tumors. And the promise of that idea helped the biotech rope in a massive $56 million B round, cash that will help get its top prospect into clinical trials.
Chinese vaccines producer Sinovac laid out big R&D plans this week to test multiple candidates--one of which has the potential to challenge Big Pharma's standing in the country.
At the annual meeting of the American Association for Cancer Research, researchers presented a gene expression model that veterinarians can use to predict how dogs with osteosarcoma will respond to the commonly used chemo drug doxorubicin, which could help both human and canine cancer patients.